Treatment of COVID-19 by CD24FC; a mini-review to the current knowledge

Abstract

The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is already known for its respiratory infection, but it involved more organs such as the kidney, liver, and heart. Most of the patients with COVID-19 have mild symptoms, but 5% of cases are admitted to an intensive care unit (ICU) for severe symptoms, including multi-organ failure and septic shock. Excessive immune responses play an essential role in sepsis development and are associated with worse prognosis in COVID-19 patients. Consequently, reduction of these immune responses may be helpful for managing COVID-19 patients. In this mini-review, we discuss the prospective role of CD24FC, as a recombinant protein with immunomodulatory function, in the treatment of COVID-19 patients and its mechanism of action in the regulation of the immune system.

Predicting the severity of COVID-19 patients using the CD24-CSF1R index in whole blood samples

“…Next, protein tyrosine kinase-binding protein (TYROBP) combined with killer-cell activating receptor-associated protein (KARAP) to form an adapter that is involved in a broad range of biological functions, such as anti-viral and anti-tumor activities [ 41 ], and displayed inflammatory reactions [ 42 ]. Sialic acid-binding Ig-like lectin 10 (SIGLEG10) expressed a large amount in B1 cells, which controls inflammation by producing interleukin-10 (IL-10), interleukin-35 (IL-35), and granulocyte-macrophage colony-stimulating factor (GM-CFS) [ 43 ]. Taken together, we found that our gene index interacts with various proteins that play important functions in immunity.…”